Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Surufatinib + Iparomlimab/Tuvonralimab + AG in Resectable Pancreatic Cancer
NCT07833241Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib, iparomlimab and tuvonralimab in pancreatic cancer (PC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Event Free Survival rate at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
surufatinibiparomlimabtuvonralimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07833241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07833241.